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Membrane localizationctor for membrane-localized Ras GTPases. Activation of RasGRP1 requires its
translocation to membranes, which can be directly mediated by either its PT or C1 domains. RasGRP1 also has
a pair of EF-hands which have been proposed to regulate RasGRP1 by sensing receptor-induced calcium
ﬂuxes. We determined that one of these EF-hands, EF1, is required for receptor-induced translocation of
RasGRP1 to the plasma membrane in B cell lines. EF1 enables plasma membrane targeting of RasGRP1 by
counteracting the SuPT domain, a negative regulator of the PT domain. Contrary to expectations, EF1-
mediated translocation of RasGRP1 does not involve antigen receptor-induced intracellular calcium ﬂux.
Instead, alternative splicing affecting EF1 serves to modulate RasGRP1 localization. Excision of an exon
encoding part of EF1 selectively disables PT domain-mediated plasma membrane targeting of RasGRP1,
without affecting C1 domain-mediated localization to endomembranes. While EF1 speciﬁcally controls PT-
mediated plasma membrane targeting, the Ras binding site in the catalytic GEF domain of RasGRP1 is
required for both PT-mediated plasma membrane targeting and C1-mediated localization to endomem-
branes. Positive feedback between its GEF domain and membrane-binding domains could be important for
full activation of RasGRP1, with occupation of the Ras binding sites in the GEF domain resulting in functional
liberation of the PT and C1 domains, and membrane binding by these domains serving to maintain the
Ras–GEF interaction.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Ras GTPases transmit signals which can modulate the proliferation,
differentiation, migration, activation and deletion of diverse cell types
[1,2]. Regulation of Ras GTPase signaling is controlled by guanine
nucleotide exchange factors and GTPase-activating proteins, which
interconvert RasGTPases between their active, GTP-bound and inactive,
GDP-bound states [3,4]. The exchange factors and GTPase-activating
proteins are themselves regulated by various signals provided by cell
surface receptors, including direct recruitment into receptor signaling
complexes, phosphorylation by receptor-coupled or distal kinases, and
recruitment to membranes by lipid second messengers such as diacyl-
glycerol (DAG), phosphatidic acid and phosphatidylinositides.
All exchange factors for Ras GTPases contain a conserved GEF
domain which directly catalyses displacement of GDP from Ras, thus
enabling its replacement by GTP [3]. Other domains of exchange
factors serve to positively or negatively regulate this process, as well as
determining where GTP-loading of Ras occurs within cells. Exchange
factor regulation has been most thoroughly examined for SOS1 [5]. Insh Columbia Cancer Research
l rights reserved.this exchange factor, the REM domain provides positive feedback
regulation by binding Ras-GTP and then allosterically enhancing the
catalytic activity of the GEF domain [6,7]. This regulatory interaction
between the REM and GEF domains may be shared by some but not all
other Ras-speciﬁc exchange factors [6]. SOS1 is also positively
regulated by recruitment to membranes, which gives it access to
lipid-modiﬁed Ras GTPases. This is achieved either by binding of SOS1
to the adapter protein Grb2 which itself binds to phosphotyrosines in
receptor-coupled signaling complexes [8], or by binding of the PH
domain of SOS1 to the lipid second messengers phosphatidic acid [9]
or phosphatidylinositol-4,5-bisphosphate [10]. The exchange activity
of SOS1 is repressed by an intraprotein interaction of its DH–PH
domain complex with the REM domain, which prevents REM-
mediated activation of the GEF domain [11]. Other Ras-speciﬁc
exchange factors can be expected to have equally complex modes of
regulation to ensure that Ras activation is coordinated with other
signal transduction events, and occurs only at the proper time and
place within cells.
RasGRPs are a family of Ras- or Rap-speciﬁc exchange factors [12]. In
RasGRP1, RasGRP3 and RasGRP4α, C1 domains canmediate localization
to membranes by binding to DAG [13–16], which is generated by
receptor-coupled phospholipase Cs [17–19]. RasGRP1 also has a PT
domain, which speciﬁcally mediates targeting to the plasmamembrane
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compact domainswhich are found in hundreds of proteins [21,22]. Most
EF-hands bind calcium, and most calcium-binding EF-hands act as
sensors of intracellular calcium ﬂuxes. When the calcium concentration
increases, these EF-hands bind calcium. The resulting conformational
shift in the EF-hand can change intra- and inter-protein interactions and
thus functionally modulate either the EF-hand-containing protein or its
interaction partners by diverse mechanisms. However, some EF-hands
are not responsive to calcium ﬂuxes, because they bind calcium with
high afﬁnity and therefore are always occupied at the basal calcium
concentration, or they bindmagnesiumand thus are always occupied by
the constitutively high concentrations of this ligand, or they do not bind
any metal ion ligand [21].
The presence of EF-hands has been widely accepted as compelling
evidence that RasGRPs are regulated by receptor-induced calcium
ﬂuxes [3,23,24]. Experiments using calcium ionophore treatment of
transfected cells have indicated that both RasGRP1 and RasGRP2
(CalDAG-GEFI) might be weakly activated by calcium [25,26]. In the
Jurkat T cell line, RasGRP1 enhances synergistic induction of
interleukin-2 expression by calcium ionophore in combination with
phorbol ester, a DAG-mimetic ligand for the C1 domain [27]. In COS
cells, RasGRP1 expression can increase GTP-loading of Ras at Golgi
membranes, and chelation of cytosolic calcium can inhibit GTP-
loading of Ras at the same site [28]. Based on these experiments, it has
been hypothesized that intracellular calcium ﬂuxes positively regulate
RasGRPs, with the assumption that this involves binding of calcium to
their EF-hands [28–30]. However, other experiments have indicated
that the catalytic activities of RasGRP4 and a splice variant of human
RasGRP2 are inhibited rather than activated by calcium, either in cells
[26] or in direct exchange assays performed in vitro [26,31,32]. None of
these studies addressed the question of whether the EF-hands of
RasGRPs are directly required for calcium-mediated activation or
inhibition. The second, but not the ﬁrst, EF-hand is needed for calcium
binding to denatured and nitrocellulose-absorbed RasGRP1 [33],
indicating that the second EF-hand might have the potential to
regulate RasGRP1 via direct binding of calcium. A deletion that
includes both EF-hands did not impede the ability of RasGRP1 to
induce Ras-mediated transformation of NIH 3T3 ﬁbroblasts [16], so
the EF-hands are not strictly required for RasGRP1 activation in these
cells. However, the same deletion eliminated the ability of RasGRP1 to
promote B cell receptor (BCR)-induced apoptosis in the WEHI 231 B
cell line [34]. Taken in combination, these various studies indicate that
if calcium- and EF-hand-mediated regulation of RasGRP1 occurs it
may be cell-type speciﬁc, or responsive to only some types of recep-
tors. Additionally, they leave open the possibility that the EF-hands of
RasGRPs may play a regulatory role that does not have a direct me-
chanistic connection to receptor-induced intracellular calcium ﬂuxes.
In this study, we have directly examined the involvement of
receptor-induced calcium ﬂuxes and the EF-hands in the regulation of
RasGRP1, the most thoroughly characterized of the RasGRPs. For this
purpose, we have used BCR-induced activation of RasGRP1 in the
DT40 B cell line, as the molecular mechanisms regulating RasGRP1
have been extensively investigated in this experimental system
[17,18,20]. In DT40 cells, BCR ligation induces translocation of RasGRP1
to the plasma membrane [17,20], which serves to activate RasGRP1 by
bringing it in contact with its membrane-bound Ras substrates. We
found that the ﬁrst EF-hand (EF1) was required for efﬁcient plasma
membrane targeting of RasGRP1 in response to either BCR or a G
protein-coupled receptor. EF1 controls plasmamembrane targeting by
counteracting the SuPT domain which negatively regulates the PT
domain. Unexpectedly, the ﬂux of calcium into the cytosol which is
induced in DT40 cells by BCR ligation is not required for translocation
of RasGRP1. Membrane localization of RasGRP1 can be controlled by
alternative splicing of exon 11, which partially encodes EF1. The Ras-
binding site in the GEF domain also controls the capability of RasGRP1
to localize to membranes via both the PT and C1 domains. Thisinterdependency of Ras-binding and membrane-binding domains
provides a potential mechanism for setting up regulatory feedback
between catalytic activity and membrane localization, which could be
critical for the initiation and maintenance of RasGRP1 activation.
2. Materials and methods
2.1. Cells and reagents
Wild-type DT40 cells were obtained fromMike Gold (University of
British Columbia, Vancouver), and were originally from T. Kurosaki
(RIKEN Research Center, Yokohama, Japan). All DT40 cells used in this
study were expressing the murine ecotropic retroviral receptor, to
make them permissible for infection with murine retroviral vectors.
DT40/M5 cells were constructed by retroviral transduction of DT40
cells with a cDNA encoding the M5 muscarinic acid receptor [35].
DT40 cells were cultured in RPMI 1640 medium (Stem Cell Tech-
nologies) supplemented with 10% fetal bovine serum (PAA Labora-
tories), 2% chicken serum (Invitrogen), and 50 μM 2-mercaptoethanol.
NIH 3T3 cells from American Type Culture Collection were cultured in
DMEM (Stem Cell Technologies) containing 10% bovine calf serum
(Fisher Scientiﬁc). WEHI-231 cells were obtained from ATCC and
cultured in DMEM containing 10% fetal bovine serum and 50 μM
2-mercaptoethanol. Anti-chicken IgM polyclonal antibody was from
Bethyl Laboratories. Anti-mouse IgM was from Jackson Immuno-
Research. Anti-extracellular signal-regulated kinase (ERK)1/2 and
anti-phospho-speciﬁc ERK1/2 antibodies were from Cell Signaling
Technology, and anti-RasGRP1 (m199) was from Santa Cruz Biotech-
nology. Horseradish peroxidase-conjugated secondary antibodies
were from Jackson ImmunoResearch Laboratories. BAPTA-AM and
Fura-2/AM were from Invitrogen. Carbachol was from Sigma-Aldrich.
The MEK1 inhibitor UO126 was from Promega.
2.2. RasGRP1 constructs
The N-terminally GFP-tagged form of full-length murine RasGRP1
(abbreviated as RG1 in this paper) was derived from the XFL construct
described previously [16,20] with the GFP coding sequences from
pEGFP-C1 (Clontech) fused to amino acid 2 of RasGRP1 (GenBank
accession no. NP 035376). The sequence at the fusion site is KSGLR-
SSAQSEGTLGKAR, with the sequences that do not naturally occur in
RasGRP1 in italics. The following constructs are modiﬁcations of this
RasGRP1 construct with the indicated changes (sequences that do not
naturally occur in RasGRP1 are italicized). RG1-EF1μ contains muta-
tions affecting the ﬁrst EF-hand. The encoded peptide sequence of this
mutant is VFKNY SL SQ SGYISQE; the normal sequence is
VFKNYDLDQDGYISQE. RG1-EF2μ contains mutations affecting the
second EF-hand. The encoded peptide sequence of this mutant is
SFCVMSKSRSGLISRD; thewild-type sequence is SFCVMDKDREGLISRD.
GEFμ1 is RG1 with a single R271E point mutation, GEFμ2 is RG1 with
a double I354A+L355A point mutation and REMμ is RG1 with a
double L123A+K124E point mutation. RG1ΔC1-PT has a deletion of
amino acids 538 to 795; the C-terminal sequence is YSKLGSPE.
RG1ΔNterm has a deletion of amino acids 1–50; the sequence at
the fusion with GFP is KSGLRSLKSTEDRVSLGHLAK. The encoded
peptide sequence of the Proμ mutation is NHRAQGLTGSKGGVVVD;
the wild-type sequence is NHRAPPLTPSKPPVVVD. RG1-Proμ, and the
form of RG1 used as its control in the experiment shown in Fig. 6D,
also had the ΔN-term mutation. RG1ΔC1=deletion of amino acids
538–595; sequence around deletion=YSKLGSTKSPAIS. RG1ΔSuPT=-
deletion of amino acids 646–694; sequence around deletion=VDH-
SEESTPRKSAQ. RG1Δex11=deletion of amino acids 442–476;
sequence around deletion=NHRAPSVFKN. RG1ΔGEFC=deletion of
amino acids 396–439; sequence around deletion=INELVQTEAPPLTP.
RG1ΔREM=deletion of amino acids 1–176; sequence at fusion with
GFP=KSGLRSFRDWSRKLT. RG1-pr and RG1-GEFμ2-pr=replacement of
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the prenylation signal of K-Ras; sequence from fusion to C terminu-
s=EPRNHRSTEAYPYDYASGSRKHKEKMSKDGKKKKK-KSKTKCVIM.2.3. Retroviral transduction of cell lines
Transfection of BOSC23 ecotropic packaging cells with retroviral
vector plasmid DNA was performed as described previously [20].
Virus-containingmediumwas supplementedwith polybrene to 20 μg/
ml and then added to an equal volume of DT40 or WEHI-231 cells
(2×106/ml) in appropriate medium. After 5 to 10 h of culture, 2 to 3
volumes of fresh medium was added to the infected cultures.
Transduced cells were selected by addition of puromycin or hygro-
mycin 30 to 48 h after infection. GFP-positive cells were then sorted by
ﬂow cytometry. Adherent NIH 3T3 cells were transduced in the same
way, except with complete changes of medium.Fig. 1. Theﬁrst EF-hand is required for receptor-induced translocation of RasGRP1. (A)DT40 cells
schematic) were untreated (nil) or treated with 5 μg/ml of α-IgM for 15 min. Cells were then ﬁ
along the indicated segments are shown to the top right of each cell image. The edge of the cell
with detectable GFP at the plasma membrane are listed to the right of each image as “% pm+”. T
except for the α-IgM-stimulated RG1-EF1μ-expressing cell which is representative of those
independent experiments. (B) Sequence of the two EF-hands in RasGRP1, showing the predicte
ligandbinding are bolded). The vertical arrows indicate themutations inEF1 and EF2 that remov
theM5muscarinic acid receptor and expressingRG1orRG1-EF1μwere untreated (nil) or treated
for ﬂuorescence microscopy, analyzed, and displayed as described for A. The results are repres2.4. Fluorescence microscopy
DT40 or WEHI-231 cells were plated on poly-L-lysine (Sigma-
Aldrich)-coated glass coverslips. Cells were stimulated in Hank's
buffer (Stem Cell Technologies) with 5 μg/ml anti-chicken IgM (DT40
cells) or anti-mouse IgM (WEHI-231 cells). For BAPTA-AM experi-
ments, cells were incubated in activation buffer (25mMHEPES, pH 7.2,
125 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM Na2HPO4, 0.5 mMMgSO4,
2 mM L-glutamine,1 mM sodium pyruvate, 0.1% glucose, 0.1% BSA, and
50 μM 2-mercaptoethanol) [36] with BAPTA-AM for 30 min and then
subsequently stimulated in activation buffer with 5 μg/ml anti-chicken
IgM. NIH 3T3 cells were cultured on glass coverslips. Cells were
ﬁxed with 4% formaldehyde in PBS for 10 min. Fixed cells were
permea-bilized with 0.2% triton X-100 in PBS and stained with
mouse anti-GM130 antibody (BD Biosciences), followed by Alexa Fluor
647-conjugated anti-mouse IgG antibody (Invitrogen). Endo-
plasmic reticulum was stained by treatment of unﬁxed cells withexpressingGFP-tagged forms of either RG1, RG1-EF1μ or RG1-EF2μ (structure illustrated in
xed and photographed by ﬂuorescence microscopy. Histograms of ﬂuorescence intensities
is indicated by the vertical line on the segment. The percentages of cells in each population
he single cells shown are representative of the typical appearance of the majority of cells,
with detectable plasma membrane localization. This experiment is representative of 3
d N- and C-terminalα-helices, and the intervening loops (residues potentially involved in
epotential ligand-bindingaspartate and glutamate residues. (C) DT40cells transducedwith
with100 μMcarbachol (an agonist for theM5 receptor) for 10min. The cellswere prepared
entative of 2 independent experiments.
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cene)-Texas Red (ER Tracker, Invitrogen) for 30 min, followed by
ﬁxation using 4% formaldehyde in PBS for 2 min.
Fluorescencemicroscopywasperformedwith anAxioplan2 imaging
microscope, using a 450–485 nm excitation ﬁlter and a 500–545 nm
emission ﬁlter for analyzing GFP-tagged constructs, and a 530–585 nm
excitation ﬁlter and 615 nm (long-pass) emission ﬁlter for analysis of
Alexa Fluor 647 or ER Tracker. Images were captured using OpenLab
imaging software and used to score between 50 and 150 cells for
localization of the GFP fusion proteins. Only cells showing ﬂuorescence
well above autoﬂuorescence levels were scored. The individual DT40 or
WEHI-231 cells displayed in the ﬁgures were chosen to be representa-
tive of the majority of the population of cells, unless otherwise noted in
the ﬁgure legends. After re-sizing images of DT40 or WEHI-231 cells as
needed to have equivalent cell diameters, histograms of ﬂuorescence
intensities along segments were drawn by the proﬁle function of Scion
Image software (version 4.0, Scion Corp. FrederickMDUSA). Each proﬁle
was generated by drawing a straight line from the centre of the cell of
interest, through and beyond the plasma membrane, as shown in the
ﬁgures. For colocalization analyses, images were separately colour
balanced and then overlayed using OpenLab software.
2.5. Stimulation and lysis of cells for western blot analysis
DT40 cells (5×106) were incubated in activation buffer for 10min at
37 °C before stimulationwith anti-chicken IgM a concentration of 5 μg/
ml for the indicated times. For BAPTA-AM treatments, cells were
incubated in activation buffer loaded with BAPTA-AM at 23 °C for
30min prior to beingwashed in the same buffer and then stimulated at
37 °C with 5 μg/ml of anti-IgM. Cells were immediately lysed with 2.5
volumes of ice-cold lysis buffer (25mMHEPES, pH 7.5,150mMNaCl,1%
NP-40, 0.25% sodium deoxycholate, 10% glycerol, 25 mM NaF, 10 mM
MgCl2, 1 mM EDTA, and 1 mM NaMoO4) containing 2 μg/ml aprotinin,
2 μg/ml leupeptin, 0.5 mM phenylmethylsulfonyl ﬂuoride, and 1 mM
activated Na3VO4. Samples containing equal quantities of total protein
(measured by the BCA protein assay; Pierce Chemicals) were denatured
usingBio-RadXTsample buffer, separated bygel electrophoresis on 12%Fig. 2. The ﬁrst EF-hand is required for BCR-induced activation of RasGRP1. DT40 cells transdu
of α-IgM for the indicated time points. Levels of phosphorylated ERK2 were determined by
each band) are normalized to unstimulated control (GFP) cells. Equal quantities of protein we
second blot with an anti-ERK1/2 antibody (lower panels). The results shown are representaXT-Criterion acrylamide gels (Bio-Rad), and transferred to polyvinyli-
dene diﬂuoride membranes (Millipore) by electroblotting. After
blocking the membranes overnight at 4 °C in TBST buffer (25 mM
Tris–HCl, pH 7.4, 3 mM KCl, 150 mM NaCl, and 0.05% Tween 20)
containing 5% BSA, primary antibodies were applied to the membrane
for 90 min at room temperature in TBST, 2% BSA, and horseradish
peroxidase-conjugated secondaryantibodieswere applied for 45min at
23 °C in TBST containing 1% BSA. Membranes were exposed to
substrate/enhanced chemiluminescence (Santa Cruz Biotechnology)
and chemiluminescence was detected using the VersaDoc 5000
imaging system (Bio-Rad). P-ERK2 was quantiﬁed by band volume
analysis using Quantity One software (Bio-Rad). In all Western blot
ﬁgures, each panel is from a single blot, with gaps in the image indi-
cating intervening segments of the blot that are not displayed.
2.6. Calcium ﬂux measurements
DT40 cells (4×106 cells per ml) were incubated with 2 μM Fura-2/
AM in activation buffer at 23 °C for 75 min. For BAPTA-AM treatments,
the cells were incubated with Fura-2-AM for 45 min at which point
BAPTA-AM was added and incubated for another 30 min. The cells
were then washed and resuspended in 1 ml of activation buffer at
2×106 cells per ml in a stirring cuvette and cells were stimulated by
addition of α-IgM (5 μg/ml). Cytosolic calcium was measured by
monitoring ﬂuorescence emission at 510 nm from excitation at 340
versus 380 nm, using an Aminco-Bowman series 2 luminescence
spectrometer (Thermo Electron Corporation).
3. Results
3.1. The ﬁrst EF-hand of RasGRP1 is essential for BCR-induced plasma
membrane targeting in DT40 cells
DT40 B cells have been used to deﬁne the molecular mechanisms
that regulate the translocation and activation of RasGRP1 in response
to BCR-initiated signal transduction [17,18,20]. Ligation of BCR by anti-
IgM induces translocation of GFP-tagged RasGRP1 to the plasmaced with GFP as a control, or with RG1, RG1-EF1μ or RG1-EF2μwere treated with 5 μg/ml
Western blot using an anti-phosphoERK antibody. Quantities of P-ERK2 (shown below
re loaded in each lane, and equivalent levels of total ERK2 were conﬁrmed by probing a
tive of 3 independent experiments.
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mediated by the PT domain in DT40 cells, with the C1 domain
providing positive cooperativity that further stabilizes localization to
the plasmamembrane [20]. BCR-induced plasmamembrane targeting
is accompanied by catalytic activation of RasGRP1, which is detectedFig. 3. EF1 is required for PT domain-mediated plasmamembrane targeting in DT40 cells, and
PT were untreated (nil) or treated with α-IgM for 15 min. The cells were prepared for ﬂuoresc
representative of 2 independent experiments. (B) DT40 cells expressing RG1, RG1ΔC1 or RG1Δ
for ﬂuorescencemicroscopy, analyzed, and displayed as described for Fig.1A. The single cells
α-IgM-stimulated RG1ΔC1-expressing cell which is representative of those with detectable
(C) DT40 cells expressing RG1, RG1-EF1μ, RG1ΔSuPT or RG1ΔSuPT-EF1μwere untreated (nil)
analyzed, and displayed as described for Fig. 1A. The single cells shown are representativ
RG1-EF1μ-expressing cell which is representative of those with detectable plasma membraby the increase in phosphorylation of ERK2 via the Ras–Raf–MEK
signaling pathway [20] (Fig. 2, comparing cells transduced with RG1
versus control cells transduced with GFP). We used this experimental
system to assess the roles of the EF-hands on BCR-induced transloca-
tion and activation of RasGRP1.does this by counteracting the SuPT domain. (A) DT40 cells expressing RG1 or RG1ΔC1-
ence microscopy, analyzed, and displayed as described for Fig. 1A. The results shown are
C1-EF1μwere untreated (nil) or treated withα-IgM for 15 min. The cells were prepared
shown are representative of the typical appearance of themajority of cells, except for the
plasma membrane localization. The results shown are representative of 3 experiments.
or treated with α-IgM for 15 min. The cells were prepared for ﬂuorescence microscopy,
e of the typical appearance of the majority of cells, except for the α-IgM-stimulated
ne localization. The results shown are representative of 3 independent experiments.
Fig. 4. EF1 is not required for C1 domain-mediated endomembrane localization or
oncogenic transformation in NIH 3T3 ﬁbroblasts. A. NIH 3T3 cells expressing either GFP
only or the GFP-tagged RG1 or RG1-EF1μ constructs were photographed by ﬂuorescence
microscopy. The results shown are representative of 3 independent experiments. B. NIH
3T3 cells expressing either GFP only, RG1 or RG1-EF1μ were cultured for 14 days and
then photographed. High refractility and loss of contact inhibition is indicative of
transformation.
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features expected of EF-hands that can bind calcium and/or
magnesium. Most notably, the amino acids at the 1, 3, 5, 7, 9 and 12
positions in the intra-helical loop of each EF-hand (Fig. 1B) are
appropriately conﬁgured for binding one of these cation ligands [21].
We made triple mutations affecting the three carboxylic amino acids
at position 1, 3 and 5. These three residues, particularly at position
1, are essential for calcium or magnesium binding by EF-hands
[21,37–39]. Therefore, the triple mutation will eliminate any potential
for ligand binding by the EF-hands, while minimally altering the
overall structure of the EF-hands. Mutation of EF2 had no detectable
effect on either RasGRP1 localization or activation (Figs. 1A and 2). In
contrast, plasma membrane-targeted translocation of RasGRP1 was
severely affected by EF1mutation.While all cells expressingwild-type
RasGRP1 showed strong translocation to the plasma membrane
following BCR ligation, this occurred in only a small proportion of
cells expressing RasGRP1 with mutation of EF1 (8% in the experiment
shown in Fig. 1A), and in those cells the mutant RasGRP1 was only
weakly translocated to the plasma membrane. EF1 mutation also
caused a major reduction in BCR-induced activation of RasGRP1
(Fig. 2). Thus, EF1 controls the plasma membrane targeting step that
leads to the activation of RasGRP1 by BCR ligation.
In DT40 cells expressing the M5 muscarinic acid receptor, reloca-
lization of RasGRP1 to the plasma membrane is induced by carbachol,
an agonist for this G protein-coupled receptor (Fig. 1C). Mutation of
EF1 abrogated carbachol-induced translocation of RasGRP1, demon-
strating that this EF-hand is important for plasma membrane tar-
geting via two distinct classes of receptors.
Under some conditions and in some cell types, RasGRP1 can
localize to Golgi rather than plasma membrane [28,40–42]. This raises
the possibility that Golgi versus plasma membrane localization of
RasGRP1 could be determined by whether EF1 is functional or not.
However, there was not any signiﬁcant concentration of RasGRP1 at
Golgi in DT40 cells, even when plasma membrane localization was
suppressed as a result of EF1 mutation (Fig. S1).
3.2. EF1 enables plasma membrane targeting of RasGRP1 by
counteracting the SuPT domain
The EF-hands are not directly responsible for plasma membrane
targeting of RasGRP1 in DT40 cells because the RG1ΔC1-PT construct,
which contains both EF-hands but lacks the C1 and PT domains, has no
detectable plasma membrane localization with or without BCR
ligation (Fig 3A). We have previously shown that efﬁcient plasma
membrane targeting of RasGRP1 in DT40 cells requires both the C1
domain and the PT domain, and can be suppressed by the SuPT
domain [20], so loss of function of either the C1 or PT domain or gain
of function of the SuPT domain could potentially explain the defect in
BCR-induced plasma membrane targeting that is caused by EF1
mutation. In NIH 3T3 ﬁbroblasts, a portion of RasGRP1 localizes to
endomembranes (predominantly to endoplasmic reticulum, and with
some Golgi localization), and this is mediated by the C1 domain with
no involvement of the PT or SuPT domains [14,16,20]. This provides an
experimental system for testing how EF1 mutation affects the C1
domain. A portion of RasGRP1 was still concentrated at endomem-
branes of NIH 3T3 cells when EF1 was mutated (Figs. 4A, S2 and S3).
Thus, EF1 does not disable C1 domain function in these cells. Mutation
of EF1 (Fig. 4B) or deletion of both EF-hands [16] also had no effect on
the ability of RasGRP1 to induce oncogenic transformation of NIH 3T3
cells, which is a read-out of the ability of RasGRP1 to catalyse GTP for
GDP exchange on Ras GTPases [16]. Because C1 deletion eliminates the
transforming activity of RasGRP1 [16,20], this further demonstrates
that C1 domain function is not disabled by EF1 mutation, and also
shows that EF1 is not essential for the catalytic function of RasGRP1.
We used deletionmutants of RasGRP1 to discriminate the effects of
EF1 mutation on the C1 versus PT versus SuPT domains in DT40 cells.When the C1 domain is deleted, BCR-induced translocation of
RasGRP1 to the plasma membrane is mediated by the PT domain,
and occurswith reduced efﬁciency due to partial suppression of the PT
domain by the SuPT domain [20]. BCR-induced translocation of
RasGRP1ΔC1 was eliminated by mutation of EF1 (Fig. 3B), conﬁrming
that the C1 domain isn't involved in the mechanism by which EF1
promotes membrane localization. Because the PT domain is essential
for plasma membrane targeting of RasGRP1 in DT40 cells, its
involvement in EF1-dependent plasma membrane targeting couldn't
be tested by deletion. However, when the SuPT domain was deleted
RasGRP1 translocation to the plasma membrane was no longer
affected by EF1 mutation (Fig. 3C). From this, we conclude that EF1
enables BCR-induced translocation of RasGRP1 to the plasma
membrane by counteracting suppression of the PT domain by the
SuPT domain.
3.3. Translocation and activation of RasGRP1 does not require
BCR-induced calcium ﬂux
BCR ligation induces a rapid increase in the concentration of
cytosolic calcium (Fig. 5A), which reﬂects release of intracellular
calcium stores into the cytosol, followed by inﬂux of calcium into the
cytosol via channels in the plasmamembrane [43–45]. To determine if
this BCR-induced calcium ﬂux is required for the EF1-dependent me-
chanism that controls RasGRP1 translocation, we treated DT40 cells
with BAPTA-AM, a cell-permeable calcium chelator which accumu-
lates in the cytosol [46]. BAPTA-AM eliminated the calcium ﬂux into
the cytosol which is induced by BCR ligation (Fig. 5A), but had no
discernible effect on BCR-induced translocation of RasGRP1 to the
plasma membrane (Fig. 5B), and also had no signiﬁcant effect on
RasGRP1 activation by BCR (Fig. 5C). Therefore, the global increase in
cytosolic calcium concentration that is triggered by BCR ligation is not
needed for either RasGRP1 activation or its translocation to the plasma
membrane.
Because chelation of calcium is limited by the on-rate of binding,
BAPTA may not fully sequester calcium in the immediate vicinity of
membrane channels [47,48]. This raises the possibility that localiza-
tion of RasGRP1 to the plasma membrane could be dependent on
Fig. 5. BCR-induced plasma membrane targeting and activation of RasGRP1 does not require BCR-induced calcium ﬂux. (A) Fura-2/AM-loaded DT40 cells were treated without (top
panel) or with (bottom panel) BAPTA-AM, and then stimulated withα-IgM. The ratio of excitation at 340 nm (Ca2+-bound Fura-2) versus 380 nm (unbound Fura-2) is proportional to
the free cytosolic Ca2+ concentration. The results shown are representative of 3 independent experiments. (B) DT40 cells expressing GFP-tagged RasGRP1 (RG1) were unstimulated
(nil) or treated with 10 μM BAPTA-AM for 30 min prior to stimulation with 5 μg/ml of α-IgM for the indicated times. Cells were prepared for ﬂuorescence microscopy, analyzed, and
displayed as described for Fig. 1A. The single cells shown are representative of the typical appearance of the majority of cells, except for the 3 min timepoints where cells
representative of those with detectable plasma membrane localization are shown. The results displayed in this ﬁgure are representative of the results of 3 independent experiments.
(C) DT40 cells expressing either GFP as a control or RG1 were either untreated (nil) or treated with 10 μM BAPTA-AM for 30 min prior to being untreated or treated with 5 μg/ml of
α-IgM for 15 min. Levels of phosphorylated ERK2 were determined byWestern blot using an anti-phosphoERK antibody. Relative quantities of P-ERK2 (shown below each band) are
normalized to unstimulated control (GFP) cells. Equal quantities of proteinwere loaded in each lane, and equivalent levels of total ERK2were conﬁrmed by probing a second blot with
an anti-ERK1/2 antibody (lower panel). The results shown are representative of 3 independent experiments. (D) DT40 cells expressing RG1were either untreated (nil) or treated with
10 μM BAPTA-AM, in either Ca2+-containing buffer or in Ca2+-free buffer containing 1 mM EGTA. The cells were either unstimulated or stimulated with 5 μg/ml of α-IgM for 15 min.
The results shown are representative of 2 independent experiments.
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membrane, with BAPTA failing to fully eliminate these calcium ﬂuxes
before they act on RasGRP1. However, chelation of extracellular cal-Fig. 6. Excision of exon 11 in RasGRP1 results in plasma membrane targeting and activation d
the GEF domain and EF1. The predicted N- and C-terminal α-helices and the intervening loo
horizontal arrow. Potential ligand-binding residues in the loop of EF1 are bolded, as are pr
indicate the proline cluster mutation (Proμ). (B) NIH 3T3 cells expressing either GFP, RG1, o
panels). The results shown are representative of 3 independent experiments. (C) DT40 cells
5 μg/ml of α-IgM for 15 min. The cells were prepared for ﬂuorescence microscopy, analyzed
typical appearance of the majority of cells, except for the α-IgM-stimulated RG1Δex11-
localization. The results shown are representative of 3 independent experiments. (D) DT40 ce
N-terminal amino acids of RasGRP1, which does not inﬂuence membrane localization (see ﬁ
15 min., then prepared for ﬂuorescence microscopy, analyzed, and displayed as described focium by EGTA in combination with chelation of cytosolic calcium by
BAPTA-AM had no effect on BCR-induced translocation of RasGRP1
(Fig. 5D), indicating that local inﬂux of calcium through plasma mem-efects that mimic EF1 mutation. (A) Location of exon 11-encoded amino acids relative to
p of EF1 are indicated. The C-terminal boundary of the GEF domain is indicated by the
olines that have the potential to form an SH3 domain-binding site. The vertical arrows
r RG1Δex11, showing protein localization (left panels) or transformation activity (right
expressing RG1, RG1Δex11 or RG1Δex11ΔSuPT were either untreated or treated with
, and displayed as described for Fig. 1A. The single cells shown are representative of the
expressing cell which is representative of those with detectable plasma membrane
lls were transduced with either RG1 or RG1-Proμ. Each of these had a deletion of the 50
gure). The transduced cells were either untreated or treated with 5 μg/ml of α-IgM for
r Fig. 1A. The results shown are representative of 3 independent experiments.
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plasma membrane.
RasGRP1 is not at the plasma membrane 1 min after BCR ligation,
when the peak of calcium ﬂux occurs, while maximal accumulation of
RasGRP1 at the plasma membrane occurs between 5 and 15 min post
BCR-ligation (Fig. 5B), by which time cytosolic calcium concentration
has declined towards basal levels (Fig. 5A). This raises the possibility
that calcium is inhibitory rather than stimulatory to RasGRP1
translocation to the plasma membrane, such that RasGRP1 can only
translocate after the calcium ﬂux has abated. However, quenching of
the calcium ﬂux with BAPTA-AM did not noticeably advance the
kinetics of RasGRP1 translocation following BCR ligation (Fig. 5B), so
the transient ﬂux of calcium into the cytosol which is induced by BCR
ligation is not responsible for the delay in plasmamembrane targeting
of RasGRP1.
3.4. Plasma membrane targeting of RasGRP1 can be modulated by
alternative splicing affecting EF1
Because BCR-induced calcium ﬂux is not required for plasma
membrane targeting of RasGRP1 while EF1 is required, control of
RasGRP1 localization by EF1 may occur constitutively rather than in
response to a BCR-induced signal. In this case, modulation of RasGRP1
localization via EF1 could be achieved by selective removal of EF1 from
RasGRP1, via alternative splicing. Absence of exon 11 is the most
common splice variation of RasGRP1, and is particularly abundant in
the lymphocytes of systemic lupus erythematosus patients [49], who
have an autoimmune disease that is mimicked in mice by RasGRP1
deﬁciency [50,51]. Exon 11 encodes 35 amino acids immediately
C-terminal to the GEF domain, and includes part of the predicted
N-terminal helix of EF1 (Fig. 6A). When expressed in NIH 3T3 cells,
RasGRP1Δex11 was localized to endomembranes and induced
transformation equivalently to full-length RasGRP1 (Figs. 6B, S2 and
S3), indicating that both the membrane localization function of the C1
domain and the catalytic activity of the GEF domain are unaffected by
removal of the amino acids encoded by exon 11. However, in DT40
cells BCR-induced plasma membrane targeting of RasGRP1Δex11 was
almost eliminated in comparison to full-length RasGRP1, and deletion
of the SuPT domain largely restored the efﬁciency of plasma
membrane targeting of RasGRP1Δex11 (Fig. 6C). Thus, deletion of
exon 11 precisely mimics mutation of EF1, in that it has no effect on C1
domain-mediated membrane localization, but impedes PT domain-
mediated plasma membrane targeting and does so via the SuPT
domain.
In addition to potentially removing part of the N-terminal helix of
EF1 (Fig. 6A), deletion of exon 11 also removes a proline-rich segment
N-terminal to EF1 which includes a putative SH3 domain-binding
motif (Fig. 6A) that has been proposed as a regulatory element con-Fig. 7. EF1 is required for efﬁcient plasma membrane localization of RasGRP1 in WEHI-231
treated with 5 μg/ml ofα-IgM for 15 min. The cells were prepared for ﬂuorescencemicroscop
of those with detectable plasma membrane localization. The results shown are representattrolling RasGRP1 localization via its interaction with adapter proteins
[52]. This raises the possibility that plasma membrane targeting could
be controlled by the combined action of the loop of EF1 (lost in the EF1
mutation) and the nearby proline cluster (lost in deletion of exon 11).
In this situation, the plasma membrane targeting defect of RasGRP1-
Δex11 could be due to the removal of this proline cluster, rather than
direct modiﬁcation of EF1. However, mutation of the prolines had no
effect on BCR-induced plasma membrane translocation of RasGRP1 in
DT40 cells (Fig. 6D). Therefore, removal of exon 11 by alternative
splicing appears to suppress plasma membrane targeting of RasGRP1
by directly disabling EF1, presumably due to truncation of the N-
terminal helix of this EF-hand. As a result, the cellular site of
localization of the Δexon 11 splice variant is partially restricted in
comparison to full-length RasGRP1, such that only the full length form
of RasGRP1 can be targeted efﬁciently to the plasma membrane in
DT40 B cells (Fig. 6C) while both the full-length and Δ exon 11 forms
can localize to endomembranes in NIH 3T3 ﬁbroblasts (Fig. 6B).
3.5. EF1 and exon 11 are required for optimal plasma membrane
targeting of RasGRP1 in the WEHI-231 B cell line
In the murine B cell line WEHI-231, there is a low level of plasma
membrane localization of RasGRP1 in unstimulated cells, and
additional translocation of RasGRP1 to the plasma membrane occurs
following BCR ligation [20]. Both constitutive and BCR-induced plasma
membrane targeting of RasGRP1 are mediated by the PT domain in
these cells, with no discernible contribution from the C1 domain [20].
Either mutation of EF1 or deletion of exon 11 reduced both consti-
tutive and BCR-induced plasma membrane localization of RasGRP1 in
WEHI-231 cells (Fig. 7). As seen in DT40 cells, loss of plasma
membrane localization due to EF1 mutation or exon 11 deletion did
not result in retargeting of RasGRP1 to Golgi membranes (Fig. S4).
3.6. The catalytic Ras binding site in the GEF domain controls membrane
localization of RasGRP1
In several classes of exchange factors, including SOS1, Vav1, Dbs,
Trio and p63RhoGEF, the catalytic GEF domain functionally interacts
with PH or C1 domains [10,11,53–56], and thus has the potential to
affect membrane localization via these lipid-binding domains. This
prompted us to determine if membrane localization of RasGRP1 could
be regulated by the GEF domain, or the other parts of RasGRP1 that are
distal to the EF-hands and C1, SuPT and PT domains. A deletion in the
C-terminal portion of the GEF domain eliminated detectable translo-
cation of RasGRP1 to the plasma membrane in response to BCR
ligation (Fig. 8A). RasGRP1 translocation was also lost when the REM
domain of RasGRP1 was deleted, while deletion of the N-terminal
region of RasGRP1 adjacent to the REM domain had no effect on BCR-B cells. WEHI-231 cells expressing RG1, RG1-EF1μ or RG1Δex11 were untreated (nil) or
y, analyzed, and displayed as described for Fig. 1A. The displayed cells are representative
ive of 4 independent experiments.
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the GEF domain or the REM domain are equally effective at elimi-
nating BCR-induced translocation to the plasma membrane.
In SOS1, and potentially in related exchange factors such as
RasGRP1, the GEF and REM domains closely interact structurally and
functionally to enable Ras binding to the catalytic site within the GEFFig. 8.Mutation of the GEF or REM domains disrupts membrane localization of RasGRP1. (A)
treated with 5 μg/ml of α-IgM for 15 min. The cells were prepared for ﬂuorescence microscop
of 2 independent experiments. (B) DT40 cells expressing RG1, RG1-GEFμ2, RG1-GEFμ1 or RG1
were prepared for ﬂuorescence microscopy, analyzed, and displayed as described for Fig. 1A.
expressing RG1 or RG1-GEFμ2 were untreated (nil) or treated with 5 μg/ml of α-IgM for 15
described for Fig. 1A. The displayed cells are representative of those with detectable plasma
from the same experiment displayed in Fig. 7, and are representative of 4 independent exper
by ﬂuorescence microscopy. The results shown are representative of 3 independent experimdomain [6,7]. Because of this, disruption of either the REM domain or
the GEF domain can impede Ras binding at the catalytic sitewithin the
GEF domain. Our observation that deletions affecting either the REM
or GEF domains eliminated BCR-induced translocation of RasGRP1
raised the hypothesis that the Ras-bound status of the catalytic site
determines membrane localization competence of RasGRP1, with RasDT40 cells expressing RG1, RG1ΔREM, RG1ΔGEFC or RG1ΔNtermwere untreated (nil) or
y, analyzed, and displayed as described for Fig. 1A. The results shown are representative
ΔSuPT-GEFμ1 were untreated (nil) or treated with 5 μg/ml of α-IgM for 15 min. The cells
The results shown are representative of 2 independent experiments. (C) WEHI-231 cells
min. The cells were prepared for ﬂuorescence microscopy, analyzed, and displayed as
membrane localization, except for unstimulated RG1-GEFμ2 cells. The results shown are
iments. (D) NIH 3T3 cells expressing RG1, RG1-GEFμ1 or RG1-GEFμ2 were photographed
ents.
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absence of Ras binding preventing membrane localization. To test this
hypothesis we used mutations in RasGRP1 that were designed to
speciﬁcally eliminate binding of Ras to the catalytic site, without
otherwise disrupting the structure of the GEF domain. Design of these
mutations was based on the known structure of the GEF domain of
SOS1 and functional data from SOS1 and the related GEF CDC25
[7,57–59]. R271E (designated RG1-GEFμ1 in Figs. 8 and 9) is a charge-
switch mutation which lies in a helix adjacent to the catalytic Ras-
binding site in the GEF domain. In CDC25, the equivalent mutation
speciﬁcally disrupts Ras binding without altering local conformation,Fig. 9. The membrane binding defect resulting from GEF domain mutation is not due to loss o
without or with co-expression of K-Ras-G12V were either untreated or treated with 5 μg/ml
using an anti-phosphoERK antibody. Quantities of P-ERK2 (shown below each band) are nor
each lane, and equivalent levels of total ERK2 were conﬁrmed by probing a second blot w
independent experiments. (B) DT40 cells expressing RG1 or RG1-GEFμ1 with or without co
15min. The cells were prepared for ﬂuorescencemicroscopy, analyzed, and displayed as desc
DT40 cells transduced with RG1 were treated with the indicated doses of the MEK1 inhibito
times. Levels of phosphorylated ERK2 were determined by Western blot using an anti-pho
unstimulated cells. Equal quantities of protein were loaded in each lane, and equivalent leve
(lower panel). The results shown are representative of 2 independent experiments. (D) DT40 c
5 μg/ml of α-IgM for 15 min. The cells were prepared for ﬂuorescence microscopy, analyz
independent experiments.as shown by the rescue of this mutation by a complementary charge-
switch mutation in Ras [59]. The R271E mutation has previously been
shown to eliminate catalytic activity of RasGRP1 [16,20]. We made
another mutation, I354A+L355A (designated RG1-GEFμ2 in Fig. 8),
removing two aliphatic chains which in SOS1 are required to stabilize
Ras binding in the catalytic pocket [7]. As intended, this mutation
eliminated catalytic activity and did so independently of any effects
on membrane localization, as shown by the inability of this mutant
form of RasGRP1 to induce transformation of NIH 3T3 ﬁbroblasts
even when constitutively membrane-bound via attachment of a K-
Ras-derived prenylation signal (Fig. S5).f signal transduction from Ras. (A) DT40 cells expressing GFP control, RG1-GEFμ1 or RG1
of α-IgM for 15 min. Levels of phosphorylated ERK2 were determined by Western blot
malized to unstimulated control (GFP) cells. Equal quantities of protein were loaded in
ith an anti-ERK1/2 antibody (lower panel). The results shown are representative of 2
-expression of K-Ras-G12V were either untreated or treated with 5 μg/ml of α-IgM for
ribed for Fig.1A. The results shown are representative of 2 independent experiments. (C)
r UO126 for 20 min prior and then stimulated with 5 μg/ml of α-IgM for the indicated
sphoERK antibody. Quantities of P-ERK2 (shown below each band) are normalized to
ls of total ERK2 were conﬁrmed by probing a second blot with an anti-ERK1/2 antibody
ells expressing RG1were treatedwith 10 μMU0126 and either untreated or treatedwith
ed, and displayed as described for Fig. 1A. The results shown are representative of 2
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in the GEF domain eliminated BCR-induced translocation to the
plasma membrane in DT40 cells (Fig. 8B). Thus, lack of Ras binding at
the catalytic site (as represented by these two mutations) correlates
with loss of translocation competence, as predicted if the GEF domain
suppresses translocation when it is not occupied by Ras. The sup-
pressive effect of catalytic site mutation on BCR-induced plasma
membrane targeting still occurredwhen the SuPT domainwas deleted
(Fig. 8B). This indicates that plasma membrane targeting by the PT
domain is directly disabled by mutation of the catalytic Ras binding
site, in contrast to the EF1mutationwhich acts via the SuPT domain to
disable the PT domain.
In WEHI-231 cells, BCR-induced translocation of RasGRP1 to the
plasma membrane was reduced by the I354A+L355 mutation, while
constitutive plasma membrane localization was eliminated (Fig. 8C).
Both of these modes of localization are mediated by the PT domain in
WEHI-231 cells [20]. In NIH 3T3 ﬁbroblasts, the PT domain is non-
functional and so makes no contribution to membrane localization
[20]. In these cells, mutation of the catalytic Ras binding site in the GEF
domain reduced endomembrane localization (Figs. 8D, S2 and S3).
Because endomembrane localization is exclusively and sufﬁciently
mediated by the C1 domain in NIH 3T3 cells [14,16,20], this indicates
that loss of Ras binding at the catalytic site in the GEF domain impedes
membrane binding by the C1 domain, and thus is mechanistically
distinct from the consequences of EF1mutation, which does not affect
C1-mediated membrane localization.
3.7. Suppression of membrane localization by mutation of the catalytic
Ras binding site does not reﬂect loss of signal transduction from Ras
How might membrane binding via the C1 or PT domains be
dependent on Ras binding to the catalytic site in the GEF domain? This
could be due to a mechanism intrinsic to RasGRP1, with Ras binding
triggering a conformational switch that converts the GEF domain from
being membrane binding-suppressive to non-suppressive, perhaps by
sequestering versus de-sequestering the C1 and PT domains. Alter-
natively, the membrane localization defect of the GEF mutant could
reﬂect loss of a signal transduction feedback mechanism, whereby
signaling initiated by Ras GTP-loading by RasGRP1 somehow
enhances membrane localization by the C1 and PT domains. Although
no candidate mechanism is known for Ras-induced signal transduc-
tion positively controlling RasGRP1 membrane localization, we tested
this possibility by determining if signal transduction from GTP-loaded
Ras could rescue the membrane localization defect of GEF-mutated
RasGRP1. Co-expression of a constitutively GTP-loaded K-Ras mutant
(G12V) with the GEFμ1 (R271E) mutant of RasGRP1 restored signaling
downstream of Ras, as indicated by the elevation of BCR-induced P-
ERK2 levels to those provided by wild-type RasGRP1 (Fig. 9A). Despite
this, the co-expressed RasGRP1-GEFμ1 still had no detectable plasma
membrane localization after BCR ligation (Fig. 9B). Conversely,
inhibition of the Ras to ERK signaling pathway by the MEK inhibitor
U0126 (Fig. 9C) did not impede BCR-induced plasma membrane tar-
geting of wild-type RasGRP1 (Fig. 9D). In combination, these experi-
ments indicate that loss of signal transduction downstream of
RasGRP1 is not responsible for the membrane binding defect of the
RasGRP1 catalytic site mutants.
3.8. A putative Ras binding site in the REM domain of RasGRP1 positively
regulates membrane localization
In SOS1, Ras-GTP binds to a speciﬁc site within the REM domain,
and this induces a conformational change that increases the efﬁciency
of Ras binding at the catalytic site within the adjacent GEF domain
[6,7]. This provides a mechanism for positive feedback regulation of
catalytic activity whereby local generation of Ras-GTP, either by SOS1
itself or another GEF [60], results in increased Ras binding at thecatalytic site in the GEF domain, and thus increases GTP-loading of Ras
by SOS1. If binding of Ras-GTP to the REM domain also occurs in
RasGRP1, and if this promotes Ras binding at the catalytic site, the
result could be positive feedback affecting membrane localization.
Increased Ras binding at the GEF site of RasGRP1 induced by the REM:
Ras-GTP interactionwould promote membrane binding by the C1 and
PT domains, thereby further increasing catalytic activity by increasing
the probability of both the GEF and REM domains encountering
membrane-bound Ras.
To determine if the putative Ras-binding site in the REM domain
positively regulates membrane localization of RasGRP1, we made a
L123A+K124E double point mutation (designated RG1-REMμ in
Fig. 10). Based on the SOS1 structure [7], this mutation is predicted
to preclude Ras-GTP binding at the REM site of RasGRP1. The
L123A+K124E mutation reduced, but did not completely eliminate,
plasma membrane localization in BCR-stimulated DT40 and
WEHI-231 B cells (Fig. 10A and B), and caused a moderate reduction
in endomembrane localization in NIH 3T3 cells (Figs. 10C, S2 and S3).
These results demonstrate that the putative Ras binding site in the
REM domain is required for efﬁcient membrane localization of
RasGRP1, both to endomembranes via its C1 domain in NIH 3T3
cells and to the plasma membrane via its PT domain in B cells. This
could be due to the Ras-GTP-bound REMdomain acting as an allosteric
positive regulator of the efﬁciency of Ras binding to the GEF site of
RasGRP1, which in turn determines the membrane-binding compe-
tence of the C1 and PT domains. However, this interpretation is based
on the assumption that the REM of RasGRP1 functions equivalently to
the REM of SOS1, which has yet to be experimentally tested.
4. Discussion
The initial analyses of RasGRP1 supported a simple model for the
function of this exchange factor, with membrane localization
conferred by its C1 domain binding to DAG and resulting in catalysis
of guanine nucleotide exchange on membrane-bound Ras GTPases
[16,25,33]. Further investigations introduced additional complexity
into this model; the PT and SuPT domains provide an alternative
mechanism for regulating plasma membrane targeting of RasGRP1
[20], while PKCs are needed to catalytically activate RasGRP1 once
membrane localization has occurred [61,62]. In this study, we have
found that critical inputs into the control of RasGRP1 membrane
localization are also provided by one of its EF-hands, and by the GEF
and REM domains.
EF1 is required for BCR-induced translocation of RasGRP1 because
it counteracts the ability of the SuPT domain to impede PT domain-
mediated plasma membrane targeting. A candidate mechanism by
which this could occur would be via a calcium-regulated interaction
between EF1 and the SuPT domain, with BCR-induced calcium ﬂux
switching on the ability of EF1 to counteract the SuPT domain.
Although the potential calcium-binding amino acids in the loop of EF1
were required to counteract the SuPT domain, the cytosolic calcium
ﬂux which is induced in DT40 cells by BCR ligation could be quenched
by BAPTA without affecting RasGRP1 translocation to the plasma
membrane. One possible explanation for these observations is that
regulation of RasGRP1 by calcium binding to EF1 does occur in BCR-
stimulated DT40 cells, with EF1 responding to a local pool of calcium
that is not fully sequestered by BAPTA. Like other chelators, the ability
of BAPTA to bind calcium is temporally restricted by its on-rate and as
a result there might be high concentrations of free calcium in the
immediate vicinity of calcium channels even when BAPTA is present.
However, we found that BCR-induced plasma membrane localization
of RasGRP1 was not dependent on extracellular calcium, indicating
that local ﬂux of calcium through plasma membrane channels is not
driving EF-hand-dependent translocation of RasGRP1.
While the potential for calcium ﬂuxes to regulate RasGRP1 should be
examined further in other experimental systems, it is quite possible that
Fig. 10. A putative Ras binding site in the REM domain of RasGRP1 is required for
efﬁcient membrane localization. (A) DT40 cells expressing RG1 or RG1-REMμ were
untreated or treated with 5 μg/ml of α-IgM for 15 min. The cells were prepared for
ﬂuorescence microscopy, analyzed, and displayed as described for Fig. 1A. The single
cells shown are representative of the typical appearance of the majority of cells, except
for the α-IgM-stimulated RG1-REMμ-expressing cell which is representative of those
with detectable plasma membrane localization. The results shown are representative of
2 independent experiments. (B) WEHI-231 cells expressing RG1 or RG1-REMμ were
untreated or treated with 5 μg/ml of α-IgM for 15 min. The cells were prepared for
ﬂuorescencemicroscopy, analyzed, and displayed as described for Fig. 1A. The displayed
cells are representative of those with detectable plasma membrane localization. The
results shown are from the same experiment displayed in Fig. 7, and are representative
of 4 independent experiments. (C) NIH 3T3 cells expressing GFP, RG1 or RG1-REMμwere
photographed by ﬂuorescence microscopy. The results shown are representative of 2
independent experiments.
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cytosolic calcium concentration. In some cases, the functions of
EF-hands are independent of calcium ﬂuxes. This can be because the
EF-hand has high afﬁnity for calcium and thus is always occupied at the
basal cytosolic calcium concentration [21]. Basal calcium levels are
critical for many cellular processes, including Ras pathway signaling in
response to EGF receptor stimulation of embryonic ﬁbroblasts [63].
Conversely, EF-hands can be non-responsive to receptor-induced cal-
cium ﬂuxes because they have very low or no afﬁnity for calcium [21].
For RasGRP1, this scenario was supported by the data from an in vitro
calcium binding assay which showed that EF1 does not detectably bind
calcium [33], although the lack of calcium binding by EF1 in this assay
might have been due to denaturation of EF1 during SDS-acrylamide
electrophoresis and blotting [64]. EF1 may functionally modulate theSuPT domain through a calcium-independent mechanism that none-
theless involves the loop of this EF-hand. Calcium-independent
functions have been identiﬁed for many other EF-hands [21,22,38,65].
This would explain both the lack of calcium binding by EF1 in vitro and
the functional requirement for aminoacids in the loop of EF1 invivo, and
would also explain the lack of requirement for BCR-induced calciumﬂux
in EF1-mediated plasma membrane targeting of RasGRP1.
While it seems surprising that RasGRP1 would contain EF-hands
but not use them to regulate its responses to BCR ligation by sensing
calcium ﬂuxes, this may reﬂect its evolutionary divergence from an
ancestral RasGRP which utilized its EF-hands to respond to receptor-
induced calcium ﬂuxes. In RasGRP1, alternative splicing appears to
replace calcium as the means of regulating EF-hand-dependent mem-
brane localization. Plasma membrane targeting via the PT domain can
be switched on or off by inclusion versus exclusion of exon 11, which
encodes part of the N-terminal helix of EF1. Alternative splicing of
exon 11 generates two functionally-distinct isoforms of RasGRP1, one
capable of both PT- and C1-mediated membrane localization and
another that is restricted to C1-mediated membrane localization. For
example, full-length RasGRP1 is targeted to the plasma membrane in
BCR-stimulated DT40 or WEHI-231 cells via the PT domain, and this
targeting is lost or attenuated by splicing out exon 11. In contrast, both
forms of RasGRP1 are equivalently localized to endomembranes in
NIH 3T3 cells, because this is mediated solely by the C1 domain and so
does not require EF1. It remains to be determined how utilization of
the PT versus C1 domains deﬁnes the site of membrane localization in
other cell types. In Jurkat T cells stimulated via TCR, RasGRP1 can be
targeted to either Golgi or the plasma membrane [13,19,28,42,66].
Golgi localization of RasGRP1 is probably mediated by the C1 domain
binding DAG. However, in Jurkat cells RasGRP1 localization to the
plasmamembrane in response toTCR plus LFA-1 signalingmay also be
driven predominantly by the C1 domain binding DAG generated at
that site [66]. Thus, the EF-hands and exon 11-encoded amino acids
may not be required for plasma membrane targeting of RasGRP1 in
Jurkat T cells, despite being required for plasma membrane targeting
in DT40 and WEHI-231 B cells.
In addition to establishing a role for EF1 in PT domain-mediated
membrane localization of RasGRP1, we found that membrane locali-
zation by both the PT and C1 domains is also controlled by the GEF
and REM domains. Point mutations speciﬁcally affecting Ras binding
at the catalytic site in the GEF domain were sufﬁcient to cause loss of
plasma membrane targeting via the PT domain, and reduced
endomembrane localization by the C1 domain. Because this mem-
brane binding defect could not be rescued by restoration of Ras
signaling and was not mimicked by inhibition of the Ras to ERK
pathway, it is probably a direct and RasGRP1-intrinsic consequence of
lack of Ras binding at the catalytic site. This conclusion is supported
by the effects of mutation of a putative Ras-GTP binding site in the
REM domain, which in SOS1 serves as an allosteric enhancer of Ras
binding to the catalytic site. In RasGRP1, mutation of the residues
potentially required for Ras-GTP binding reduced the efﬁciency of
both C1- and PT-mediated membrane localization of RasGRP1. It
remains to be established whether this is due to loss of Ras-GTP-
mediated allosteric regulation of the GEF domain, as we hypothesize.
Unlike SOS1, the catalytic activity of the exchange factor RasGRF1
does not appear to be regulated by Ras-GTP binding to its REM
domain [6], so RasGRP1 may or may not share this mode of
regulation with SOS1. Irrespective of the precise contribution of the
REM domain, it is evident that the catalytic and membrane binding
functions of RasGRP1 are co-dependent. Because of this, a transition
from negative to positive feedback between these two functions
probably plays a critical role in initiating and maintaining both
membrane localization and activation of RasGRP1. Our current model
of RasGRP1 regulation via interplay between its Ras-binding and
membrane-binding domains is shown in Fig. 11. When the catalytic
site of the GEF domain is not occupied by Ras, RasGRP1 is inactive as
Fig. 11. Speculative model of feedback regulation of RasGRP1 membrane localization
and activation. Binding of Ras-GTP to the REM domain (1) increases the efﬁciency of
binding of Ras to the catalytic site within the GEF domain (2). As well as enabling Ras-
GTP generation by nucleotide exchange (3), Ras binding at the catalytic site triggers
functional liberation of the C1 and PT domains (4). If DAG and/or the PT ligand are
present in a membrane, e.g. by their induction by BCR ligation, RasGRP1 is then stably
bound to that membrane via the C1 and/or PT domains (5), thus increasing its
encounters with membrane-bound Ras. The resulting high production of Ras-GTP
increases REM occupancy by Ras-GTP, thus increasing Ras binding to the catalytic site,
thus increasing availability of the C1 and PT domains for membrane binding, thus
increasing Ras-GTP binding by the REM domain and Ras binding by the GEF domain, etc.
This positive feedback-driven activation process can be reversed either by removing
Ras-GTP, or by removing the C1 and/or PT ligands, potentially returning RasGRP1 to its
fully inactivated state. Subscripts indicate ligand occupancy, with 0 meaning
unoccupied. The brackets around the C1 and PT domains indicate functional inacti-
vation, imposed by the GEF domain when its catalytic site is not occupied by Ras.
460 G. Tazmini et al. / Biochimica et Biophysica Acta 1793 (2009) 447–461an exchange factor but is also restricted in its ability to bind mem-
branes because both the C1 and PT domains are functionally
impaired. This may involve sequestration of the C1 and PT domains
by the GEF domain, analogous to the co-sequestration of catalytic and
membrane-binding domains that regulates the progressive activation
of protein kinase Cs, chimaerins and Src family kinases [67–69]. The
resulting curtailment of the membrane binding capability of RasGRP1
lowers the probability of either the REM or GEF domains encounter-
ing membrane-localized Ras, thus setting up negative feedback
between membrane binding and catalytic activity that would tend
to maintain RasGRP1 in a fully inactive state. However, the feedback
could start working in the other direction. Occupation of the catalytic
site by Ras, perhaps facilitated by transient membrane binding via the
C1 domain, would functionally liberate both the C1 and PT domains
and thus enable stable membrane binding. This would increase the
probability of a subsequent encounter of the GEF domainwith another
Ras, which would prevent re-sequestration of the C1 and PT domains,
whichwould further promotemembrane binding and thus increase co-
localization of RasGRP1 with Ras. This positive feedback loop could be
further accelerated by the allosteric regulation provided by the REM
domain, which by binding Ras-GTP generated by the adjacent GEF
domain would increase the probability of the GEF domain binding
another Ras. This would amplify both catalytic activity (thus increasing
the probability of the REM domain remaining bound to Ras-GTP), and
membrane binding by keeping the C1 and PT domains exposed to their
ligands. Sustained RasGRP1 activationwould require continual genera-
tion of the ligands for the PT and C1 domains, e.g. via BCR ligation.
Removal of any of the positive stimuli would switch this system back
towards negative feedback. For example, a decline in DAG via co-
localization of RasGRP1 with a DAG kinase [70–72] would reduce
membrane localization, leading to a lower probability of binding either
Ras-GTP or Ras, leading to sequestration of both the C1 and PT domains
and a further decrease in Ras binding. Similarly, activation of a GAP such
as CAPRI [73] would remove Ras-GTP, thus increasing the probability of
the GEF domain being unoccupied by Ras, thus preventing membrane
binding even if C1 and PT ligands were present, etc.Because of the proposed inﬂuence of the REM:Ras-GTP interaction
on membrane binding, the intracellular location of RasGRP1 activation
could be partially determined by where other Ras-GTP-generating
exchange factors are localized. RasGRP1 has been shown to provide the
Ras-GTP needed for allosteric activation of SOS1, but under some cir-
cumstances RasGRP1 could itself be dependent on Ras-GTP generation
from other GEFs. RasGRP1 catalytic activity is also dependent on its
phosphorylation by protein kinase Cs [61,62], which themselves are
spatially regulated by the coordinated interaction of multiple domains
which respond to DAG, calcium and phosphatidylinositides and control
both membrane binding and catalytic activation [74,75]. Therefore,
speciﬁcation of the locale and quantity of RasGRP1 activation will be
directedby both the functional interplay between its REM,GEF, EF-hand,
C1, SuPTand PT domains and concurrent spatial regulation of PKCs, DAG
kinases, GAPs and other Ras-speciﬁc exchange factors.
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